Antibody response to ChAdOx1 nCoV-19 (Covishield®) vaccine in people on maintenance hemodialysis.

Dharmendra Singh BhadauriaPrachi TiwariAmit GoelHarshita KatiyarAnupma Kaulnull MayankAmita AggarwalAlka VermaDhiraj KhetanMonika YachhaManas Ranjan BeheraBrijesh YadavKartik AgarwalNarayan Prasad

Published in: Seminars in dialysis (2023)

Two doses of ChAdOx1 nCoV-19/AZD1222 (Covishield®) vaccine, given 12 weeks apart, achieve a high titer of ASAb and a high percentage of NAb in people on hemodialysis.

Keyphrases

end stage renal disease
peritoneal dialysis
chronic kidney disease
advanced non small cell lung cancer